Future studies and moving forward
Although the CDK inhibitors have primarily been tested on breast cancer patients, researchers are currently seeking applications in other types of cancer. In an ideal situation, the low risk and high safety rating of these new drugs could be extended to cancers such as lung cancer, prostate cancer, and ovarian cancer.
Gabriel Hortobágyi, a practitioner at MD Anderson Cancer Center in Houston, TX, praised the review conducted by Bardia and his team, saying that the article "summarizes the published toxicity data of the three leading CDK 4/6 inhibitors and provides clear, practical guidelines for managing the more common side effects and toxicities. Bringing together this information into one objective manuscript is a good service to the community."